Foam Sclerotherapy

Summary

Since October 2009, the use of Athoxysklerol^® foam has been approved in Germany as an option for treating varicose veins. According to the current guidelines, foam sclerotherapy can be used for all types of varicose veins. It has proved itself particularly useful for treating branch varicose veins and perforators, and as a non-surgical alternative for trunk varicose veins.

Apart from the history and clinical examination, the prerequisites for planning and carrying out foam sclerotherapy include mapping the veins by means of careful duplex ultrasound scanning of the standing patient. Once a decision for sclerotherapy has been made, patients must be fully informed about the treatment and give their consent in writing.

For the venepuncture, patients should be standing or sitting down. If the varicose veins are clearly visible or the venepuncture is performed under ultrasound guidance, the patient can be recumbent. The foam should always be applied with the patient lying down. The Tessari and DSS systems are well-established methods of producing foam. After injection of the foam, compression should be applied at the injection site, a local compression bandage applied, and finally a medical compression stocking put on top.

The adverse effects of foam sclerotherapy do not differ substantially from those of liquid sclerotherapy. Duplex ultrasonography is appropriate for monitoring therapeutic success.

Keywords

Foam sclerotherapy - Polidocanol - indication - contraindication

• Literatur

• 1 Breu FX, Guggenbichler S, Wollmann JC. Second European Consensus Meeting on Foam Sclerotherapy. Duplex ultrasound and efficacy criteria in foam sclerotherapy from the 2nd European Consensus Meeting on Foam Sclerotherapy 2006, Tegernsee, Germany. Vasa 2008; 37: 90-95.
• 2 Frullini A, Barsotti MC, Santoni T, Duranti E, Burchielli S, Di Stefano R. Significant endothelin release in patients treated with foam sclerotherapy. Dermatol Surg 2012; 38: 741-747.
• 3 Kobus S, Reich-Schupke S, Pindur L, Altmeyer P, Stucker M. Ascending thrombophlebitis after foam sclerotherapy as first symptom of breast cancer. J Dtsch Dermatol Ges 2009; 7: 239-240.
• 4 Kobus S, Reich-Schupke S, Altmeyer P, Stücker M. Aktuelle Aspekte der Schaumverödungstherapie. Phlebologie 2010; 39: 193-200.
• 5 Rabe E, Pannier F, Gerlach H, Breu FX, Guggenbichler S, Wollmann JC. Leitlinie: Sklerosierungsbehandlung der Varikose. Phlebologie 2008; 37: 27-34.
• 6 Rabe E, Pannier F. Sclerotherapy of varicose veins with polidocanol based on the guidelines of the German Society of Phlebology. Dermatol Surg 2010; 36 (Suppl. 02) 968-975.
• 7 Reich-Schupke S, Altmeyer P, Stücker M. Therapie der Stammvarikose der Vena saphena magna mittels kathetergestützter Mikroschaum-Sklerosierung ohne Heparinprophylaxe – Kleine Fallserie und Literaturübersicht. Phlebologie 2008; 37: 198-203.
• 8 Reich-Schupke S, Altmeyer P, Stücker M. Triple-lumen double-balloon catheter for foam sclerotherapy of the great saphenous vein: critical review on preliminary results. Phlebology 2010; 25: 241-245.
• 9 Stücker M, Kobus S, Altmeyer P, Reich-Schupke S. Review of published information on foam sclerotherapy. Dermatol Surg 2010; 36 (Suppl. 02) 983-992.
• 10 Reich-Schupke S, Doerler M, Altmeyer P, Stücker M. Foam sclerotherapy with Enoxaparin-prophylaxis in high-risk patients with postthrombotic syndrome. Vasa 2013. 42 in press